Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
49
MIRA Quote, Financials, Valuation and Earnings
Last price:
$1.52
Seasonality move
:
7.97%
Day range:
$1.55 - $1.59
52-week range:
$0.73 - $2.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
8.76x
Volume:
48.3K
Avg. volume:
265.8K
1-year change:
43.64%
Market cap:
$66.2M
Revenue:
--
EPS (TTM):
-$1.52
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MIRA
MIRA Pharmaceuticals, Inc.
|
-- | -$0.08 | -- | -72.73% | $17.75 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MIRA
MIRA Pharmaceuticals, Inc.
|
$1.58 | $17.75 | $66.2M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
NNVC
NanoViricides, Inc.
|
$1.19 | $6.50 | $21.4M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.84 | $2.00 | $687.2K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MIRA
MIRA Pharmaceuticals, Inc.
|
-- | 1.403 | -- | 89.82x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MIRA
MIRA Pharmaceuticals, Inc.
|
-- | -$1.3M | -935.53% | -935.53% | -- | -$1.1M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
MIRA Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns MIRA or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to MIRA Pharmaceuticals, Inc.'s net margin of -255.85%. MIRA Pharmaceuticals, Inc.'s return on equity of -935.53% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital MIRAMIRA Pharmaceuticals, Inc.-- -$1.18 $7.5M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About MIRA or NBY?
MIRA Pharmaceuticals, Inc. has a consensus price target of $17.75, signalling upside risk potential of 1023.42%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that MIRA Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe MIRA Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MIRAMIRA Pharmaceuticals, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is MIRA or NBY More Risky?
MIRA Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock MIRA or NBY?
MIRA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. MIRA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRA or NBY?
MIRA Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. MIRA Pharmaceuticals, Inc.'s net income of -$22.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, MIRA Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MIRA Pharmaceuticals, Inc. is -- versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRAMIRA Pharmaceuticals, Inc.-- -- -- -$22.7M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns MIRA or NNVC?
NanoViricides, Inc. has a net margin of -- compared to MIRA Pharmaceuticals, Inc.'s net margin of --. MIRA Pharmaceuticals, Inc.'s return on equity of -935.53% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital MIRAMIRA Pharmaceuticals, Inc.-- -$1.18 $7.5M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About MIRA or NNVC?
MIRA Pharmaceuticals, Inc. has a consensus price target of $17.75, signalling upside risk potential of 1023.42%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 446.22%. Given that MIRA Pharmaceuticals, Inc. has higher upside potential than NanoViricides, Inc., analysts believe MIRA Pharmaceuticals, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MIRAMIRA Pharmaceuticals, Inc.0 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is MIRA or NNVC More Risky?
MIRA Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock MIRA or NNVC?
MIRA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MIRA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRA or NNVC?
MIRA Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. MIRA Pharmaceuticals, Inc.'s net income of -$22.7M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, MIRA Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MIRA Pharmaceuticals, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRAMIRA Pharmaceuticals, Inc.-- -- -- -$22.7M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns MIRA or OGEN?
Oragenics, Inc. has a net margin of -- compared to MIRA Pharmaceuticals, Inc.'s net margin of --. MIRA Pharmaceuticals, Inc.'s return on equity of -935.53% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital MIRAMIRA Pharmaceuticals, Inc.-- -$1.18 $7.5M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About MIRA or OGEN?
MIRA Pharmaceuticals, Inc. has a consensus price target of $17.75, signalling upside risk potential of 1023.42%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 139.49%. Given that MIRA Pharmaceuticals, Inc. has higher upside potential than Oragenics, Inc., analysts believe MIRA Pharmaceuticals, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MIRAMIRA Pharmaceuticals, Inc.0 0 0 OGENOragenics, Inc.1 0 0 -
Is MIRA or OGEN More Risky?
MIRA Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock MIRA or OGEN?
MIRA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MIRA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRA or OGEN?
MIRA Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. MIRA Pharmaceuticals, Inc.'s net income of -$22.7M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, MIRA Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MIRA Pharmaceuticals, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRAMIRA Pharmaceuticals, Inc.-- -- -- -$22.7M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns MIRA or PTN?
Palatin Technologies has a net margin of -- compared to MIRA Pharmaceuticals, Inc.'s net margin of --. MIRA Pharmaceuticals, Inc.'s return on equity of -935.53% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MIRAMIRA Pharmaceuticals, Inc.-- -$1.18 $7.5M PTNPalatin Technologies-- -- -- -
What do Analysts Say About MIRA or PTN?
MIRA Pharmaceuticals, Inc. has a consensus price target of $17.75, signalling upside risk potential of 1023.42%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than MIRA Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than MIRA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MIRAMIRA Pharmaceuticals, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is MIRA or PTN More Risky?
MIRA Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock MIRA or PTN?
MIRA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MIRA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRA or PTN?
MIRA Pharmaceuticals, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. MIRA Pharmaceuticals, Inc.'s net income of -$22.7M is higher than Palatin Technologies's net income of --. Notably, MIRA Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MIRA Pharmaceuticals, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRAMIRA Pharmaceuticals, Inc.-- -- -- -$22.7M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns MIRA or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to MIRA Pharmaceuticals, Inc.'s net margin of --. MIRA Pharmaceuticals, Inc.'s return on equity of -935.53% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital MIRAMIRA Pharmaceuticals, Inc.-- -$1.18 $7.5M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About MIRA or TOVX?
MIRA Pharmaceuticals, Inc. has a consensus price target of $17.75, signalling upside risk potential of 1023.42%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3497.12%. Given that Theriva Biologics, Inc. has higher upside potential than MIRA Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than MIRA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MIRAMIRA Pharmaceuticals, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is MIRA or TOVX More Risky?
MIRA Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock MIRA or TOVX?
MIRA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MIRA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRA or TOVX?
MIRA Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. MIRA Pharmaceuticals, Inc.'s net income of -$22.7M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, MIRA Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MIRA Pharmaceuticals, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRAMIRA Pharmaceuticals, Inc.-- -- -- -$22.7M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 1.54% over the past day.
Buy
64
ZCSH alert for Dec 26
Grayscale Zcash Trust (ZEC) [ZCSH] is down 3.73% over the past day.
Buy
60
AAOI alert for Dec 26
Applied Optoelectronics, Inc. [AAOI] is down 9.39% over the past day.
